Good morning and welcome to the ImmuCell Corporation reports Fourth Quarter Fiscal Year 2020 Financial Results Conference Call. All participants will be in a listen-only mode. After today's presentation, there will be an opportunity to ask questions. Please note this event is being recorded. I would now like to turn the conference over to Joe Diaz with Lytham Partners. Please go ahead.

Thank you, Grant. Good morning and welcome to all out there. As Grant indicated, my name is Joe Diaz, I'm with Lytham Partners, we’re the investor relations consulting firm for ImmuCell. We thank you for joining us today to discuss the unaudited financial results for the year ended December 31, 2020. I would like to preface this discussion today with a caution regarding forward-looking statements. Listeners are reminded that statements made by management during the course of this call include forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those discussed today. Additional information regarding these risks and uncertainties is available under the cautionary note regarding forward-looking statements provided with last night’s press release. With that said, let me turn the call over to Michael Brigham, President and CEO of ImmuCell Corporation after which we will open the call for your questions. Michael?

Great, thanks Joe. I appreciate the opportunity to provide some updates on what is going on at ImmuCell. It's a very exciting time here. The press release we disclosed last night covers the key financial highlights for the year ended December 31, 2020. We expect to file our Form 10-K providing much more detail around March 30th. As you may know, we issued a press release covering our preliminary top line sales results on January 7th. We've been making these optional filings to give investors a very timely look at what I view as the most critical measure of our operations and financial performance early in the reporting period. There has been no change to our previously disclosed sales results. Product sales were up 12% for the year ended December 31, 2020, in comparison to 2019. This growth is very important for us, and it comes with consistent market share gains as well. Simply put, our sales team continues to disrupt the traditional scour vaccine market by replacing very old vaccine technology with our preformed antibodies. Beyond the top line results that I have just discussed and were previously disclosed, the three most important things that I want to talk to you about today are one, the status of our investment to expand our production capacity; two, the road to regulatory approval of Re-Tain; and three, our cash flows. So first, the status of our investment to expand our production capacity. We had a backlog of orders worth about $1.8 million as of 12/31/2020, compared to no backlog as of 12/31/2019. This strong indication of demand for our product is a good thing and confirms the need for our expanded production capacity because we need to get every dose that our customers want into their hands. The leasehold improvements to our new formulation fill and assembling facility were completed during 2020. The final phase of this project, which involves a 100% increase in our liquid processing operations and a 50% increase in our freeze drying operation, is on budget and on schedule for completion during the second quarter of 2021. This work is being carefully coordinated to minimize disruption to our ongoing operations and product supply. Before this expanded capacity comes online, we do expect to incur a decrease in sales during the first quarter of 2021 in comparison to the first quarter of 2020. This estimate of sales for the first quarter of 2021 amounts to about 92% of the $4.1 million that we estimate to be our current production capacity per quarter. We sold product equivalent to about 91% of this estimated quarterly capacity during the fourth quarter of 2020. We are working to fulfill this backlog and return to a growth mode during the second half of 2021, provided that we capture anticipated demand and end the year with available inventory on the shelf, ready for peak season sales during the first quarter of 2022, provided that we effectively complete our production capacity expansion investment. Second, the road to regulatory approval of Re-Tain. Product development expenses continue to be our largest operating expense line item, increasing by 18% to $4.4 million during 2020, including $1.5 million in non-cash depreciation expense. Let's talk about Re-Tain a bit. It's been a long and expensive road, but we are nearing completion of the work required to achieve FDA approval of this novel subclinical mastitis treatment for lactating dairy cows without a milk discard. We recently submitted the last of five significant technical sections required for FDA approval. This one is known as the Chemistry Manufacturing and Controls (CMC) Technical Section. This kind of submission is subject to a six-month review by the FDA that puts us at a crucial juncture during the third quarter of 2021. If the FDA has questions for us, we could be required to respond through another submission, which would be subject to an additional six-month review. We do not anticipate that an additional submission would be required after that. Therefore, we are making plans for a mass market launch during the second quarter of 2022 while also being prepared to execute an initial limited launch plan during the fourth quarter of 2021 if approval comes through in response to our first submission. Thirdly, and lastly, our cash flows. I think we should focus on our cash flows more than on our GAAP net loss at this stage in our development. Page 5 of last night's press release provides a look at the impact of non-cash expenses on our financial results. We reported increases in both EBITDA and what I describe as a measure of cash flows, which I believe is most relevant to tracking our performance. While both are important metrics to consider in understanding our cash flows, the most important measure is the statement of cash flows that will be included with our Form 10-K filing around the end of March. Subject to completion of our audit, we do expect to see a year-over-year increase in net cash provided by operating activities of approximately $1.1 million, which included the benefit of $938,000 in other income from the forgiveness of our paycheck protection program loan from the federal government. So in conclusion, I encourage you to review the press release that we filed last night. Also, please have a look at our corporate presentation slide deck; a February update was just posted to our website last night. I believe it provides a very good summary of our business strategy and objectives, as well as our current financial results. See the investor section on our website and click on corporate presentation or just contact our office and we can send you out a copy. With that said, I will be happy to take your questions. Let's have the operator open up the lines.

Looks like we have a question from Sam Rebotsky with SER Asset Management. Please go ahead.

Good morning, Michael. Now tell me, you were expecting to submit the Re-Tain information on December 31, so presumably we just submitted it and could you discuss why it took us so long to put all the pieces together?

Yeah, just simply, Sam, by the way, good morning. Just a very complex submission, so yes, months ago, I'm actually not sure exactly how many months we made that projection for year-end. We did not meet it, and I'm okay with that; to meet the previously disclosed deadline with less than our best effort would have been a foolish prize. So we took the time we needed to get it right, and just understand it is a very, very complex submission involving data and input from other parties. When it was ready and when it was right, it was submitted, and as I said, recently submitted, so plus or minus weeks on something like that magnitude, I think it is a bit of a rounding error. Sooner would have been premature.

So we got all the data that we needed from Norbrook and presumably that we're more comfortable on the submission, did the FDA respond in any way to our submission?

No, they won't do that. We wouldn't expect them to do that. I mentioned it's a statutory review period. While there could be some back and forth during those six months, we wouldn't expect their response until that review period is completed.

When do we expect the next quarter that will be short on getting everything to about 90% submitted, and during the second quarter, do we anticipate being fully able to submit the product?

Right, so it's pretty much an on-off switch, Sam. That 90%, 91%, 92% different periods, slightly different percentages but over 90% of our current capacity is what we do today. And our current capacity is about $16.5 million per year. As hard as we push that plant and as hard as we push our staff, we keep coming up to that similar number. Then when the new line comes on, it's mostly about more freeze drying, mostly about more liquid processing. When that comes online, we move from $16.5 million annual capacity to $23 million annual capacity. So it's at $23 million that we need to be at because that gives us a little bit of headspace over the $15.3 million that was current sales for 2020.

So the $23 million do we know which quarter we expect to or do we have…?

Next quarter, all this work will be completed and we will transition from the backlog. This will help us meet ongoing demand and start building some inventory so that we are not looking at this backlog as we enter the second half of 2021. Most importantly, we aim to prepare for peak season sales in the first quarter of 2022.

Sounds good, Michael, it's been rather a struggle, I guess, with the cold weather and everything else. Good luck to the whole ImmuCell team.

Hey Sam, appreciate that.

Thank you.

Yeah, thanks for tracking so closely. Appreciate it, Sam. Good.

Our next question will come from George Melas with MKH Management. Please go ahead.

Good morning, Michael.

Hey there, George, good morning.

Good morning. It looks like orders in the quarter were quite strong because I think you started the quarter with a backlog of just 100,000 and you ended with 1.8, so it looks like you had orders in the quarter of, I think, more than $5 billion, is that correct and how does that compare with the prior years?

George, I'm not following that math. The backlog at the end of the year, 12/31/2020, was $1.8 million. That compares to zero as of 12/31/2019. So as we come into the first quarter of 2021, we had that $1.8 million of orders yet unmet as we continue to work through that in the first quarter here. But maybe I didn't get the question, does that answer make sense?

Could you clarify if the orders in the fourth quarter were strong, considering you fulfilled some and had an additional $1.8 million in orders that were left unfulfilled?

Oh, definitely. In the fourth quarter, things really started to take off. There was a substantial amount of demand during that period, and since we had a larger backlog, we managed to reduce it to a lower level by September 30, 2020, and it just continued to grow robustly.

And that part you related to the strength of the dairy industry or what would you attribute that to because it seemed like orders sort of exploded in the fourth quarter?

Right. I see where you're going. Yes, well obviously a lot of factors. The dairy industry has been very volatile through this COVID pandemic, but towards the end of the year, it became very strong. It suffered in the early part of March, April, May with very low milk prices rebounding as has the whole food service system sort of adjusted from schools and restaurants to more take out. The adjustment here was that I've got a good chart on milk price I could share with you. It just was very, very low there in March, April, May, and then rebounded to a very high price. So the industry ended strong so that times out to the strong fourth quarter. So that probably is related. I like to think that what's really going on is the sales team is just as I mentioned in my talk there, they're having great success with this new effort to replace traditional vaccines. I mean, the addition of our rotavirus claim on top of the E. coli and Corona makes our product very attractive, and we're having great success. It's a great conversation to have about, hey, you're immunizing your cow, why, what if you left that cow alone, didn't stick a needle in or didn't subject yourself to this variable vaccine response? Let ImmuCell do the work for you. We'll give you preformed antibodies measured out in a dose, and you can give it just to that newborn calf. So I think it's a combination of great work by the sales team and a strong market that rebounded from the early COVID pandemic lows.

Okay, okay, I think that provides some good explanation because I mean, I think the audit numbers just some simple math, very, very strong. So I think that goes really well for the expansion of capacity that will come online very soon.

Yeah, it's very needed. I think that's a very, very good investment and just needed as soon as possible.

And just Michael, is the sales team still nine people or how has that changed?

Yeah, we're at the same level. We had a couple of open positions during the year, but we're level at nine. So we're full staff. And that's the seven Regional Marketing Manager, Sales and Marketing Managers, and a Director of Marketing, and then Bobbi Jo Brockmann, the VP of Sales.

Great. Okay, thank you very much.

Hey, good George. Thank you.

There being no further questions, it looks like we have a question from Scott Costa, who is a private investor. Please go ahead.

First of all, congratulations, great work especially in terms of what's been going on over the last year. It seems as though you've penetrated the market quite substantially and obviously no one has a crystal ball, but to what extent do you think that you have further penetration developable in the market?

Yeah, thanks Scott. Part of my answer, I'm going to refer you to our slide deck, because I think the numbers and the details there, I referred to growing market share as well as growing sales. The slide is around 14, 15, 16 really define what I see as the market. So there's some pie charts there and we're showing this continual and consistent growth in market share. And we define the market in two ways; one, the direct competition of products that are given to the newborn calf. And then this larger market that I have just started to discuss in a little bit with the prior question including those dam vaccines, those vaccines given to the mother cow. So, about $22 million on that calf level, about $42 million when you include the mother cow. So that's our opportunity and that's the market that we keep competing in. And those percentages we have a pie chart there, just our share is red, getting up to 41% of that calf level and up to 13% of that when you combine in the dam vaccine market. So, that leaves 87% available.

Right, okay, thank you. And that would be more of a countrywide domestic market, correct?

Yeah, you're absolutely right. This is only those numbers and those charts are just U.S. So we are up into Canada, we're having some good sales results up there. We're into a few other territories in a small way. And the longer-term plan coming out of backlog and having this capacity in place would be to continue to grow in other international markets. But that really wouldn't help us right now in 2020, that would have just added to our backlog.

No, absolutely, it is a good problem to have.

A nice problem to have, that's a good way to put it. Thank you, Scott.

Yeah. Thank you so very much.

Great, thanks.

Our next question will come from Louis Parks with Tyro Capital Management. Please go ahead.

Hi Michael, Happy New Year and thanks for the update. My question actually piggybacks on what you were just discussing. I was going to ask you to expand a little bit upon the international sales strategy?

Currently, our focus is primarily on North America, though we are also making inroads in South Korea and Japan. We've begun the necessary regulatory work and plan to collaborate with local experts to navigate these different systems, as each region has its own regulatory requirements similar to those of the USDA. Since our product needs in-country regulatory approval, we have decided not to hire additional sales representatives in these territories. Instead, we will partner with a distributor who will handle the sales while we take on the manufacturing side and assist with regulatory processes. This transition is led by Bobby. We want to make sure we don’t overwhelm new customers or add to our backlog, so we’re approaching this in stages. As we move into 2022 and beyond, I believe there are numerous global opportunities we'll begin to pursue.

Thank you.

There being no further questions, this will conclude our question-and-answer session. I'd like to turn the conference back over to Joe Diaz for any closing remarks.

Hey Grant, we may have lost Joe there but I've got the script and I know he was just going to have us close. Joe, is that you coming back?

I'm on. I am on. Again, as I was going to say, that I would like to thank everybody for participating in the call today, and we're certainly looking forward to talking with everyone again to review the results of the current first quarter of 2021, sometime around the second week of May. So have a great week. Stay safe and well, thanks to everyone. And Michael, thanks to you.

The conference has now concluded. Thank you for attending today's presentation. You may now disconnect.